Jenner, Dr Matthew

JENNER MatthewMBBS, MRCP, FRCPath                                        

Specialty

Haematology

Sub-specialty

Haematological oncology

Training and education

  • MBBS, Newcastle upon Tyne, 1997
  • MRCP, Royal College of Physicians of London, 2000
  • FRCPath, Royal College of Pathologists, 2009

Experience

Dr Jenner was appointed consultant haematologist at the Trust in November 2009. He has been clinical lead for haematology since March 2012, with managerial responsibility for the clinical and laboratory service incorporating laboratory diagnostic haematology, general haematology, haematological oncology, blood and marrow transplantation and haemostasis/thrombosis.

Dr Jenner undertakes a weekly myeloma clinic as well as a transplant follow-up clinic and alternate week lymphoproliferative and myeloid disorders clinics. He is actively involved in haemato-oncology diagnostics, including the use of immunophenotyping and molecular genetic techniques in diagnosis.

Clinical interests include the diagnosis and management of haematological malignancies utilising chemotherapy, novel agents, high dose chemotherapy and stem cell transplantation. Dr Jenner leads the myeloma team at the Trust with direct responsibility for clinical management of myeloma and paraprotein-related disorders including AL amyloidosis and POEMS syndrome. He runs a weekly all day myeloma clinic for this patient group and accepts referrals both from primary care as well as referrals from other hospitals for specialist input, including for clinical trials and transplantation. Dr Jenner is principal investigator of a portfolio of myeloma clinical trials encompassing all stages of the disease. He also chairs the Central South Coast (Western) leukaemia and myeloma multidisciplinary team meeting.

Dr Jenner undertook four years of research in to the genetics abnormalities within myeloma at the Institute of Cancer Research and Royal Marsden Hospital between 2005 and 2009. He continues to have an active interest in the role of genetic abnormalities in myeloma and their impact on treatment outcomes.

Key achievements

  • Member of NICE myeloma clinical guidelines group. Guidelines currently under development.
  • Co-authored 2013 update to British Committee of Standards in Haematology guidelines for the diagnosis and management of multiple myeloma.
  • Member of NCRI haematological oncology myeloma clinical trials subgroup.

Awards and prizes

  • Nominated for Daily Echo Hospital Heroes award 2012.

Research

Dr Jenner has conducted clinical research into the optimal treatment strategies for myeloma and in to the prognostic significance of cytogenetic abnormalities in myeloma. He has also participated in the development of BCSH and NICE myeloma guidelines.

Find out more about Dr Jenner's main publications.

Contact

You can contact Dr Jenner via his secretary Suzanne Murray on 023 8120 4438, email Suzanne.Murray@uhs.nhs.uk or fax to 023 8120 6011.

Dr Jenner sees NHS and private referrals at the Trust.